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Abstract
BACKGROUND: Previous studies showed reduction of brain cannabinoid CB1 receptors in 
adults with cannabis and alcohol use disorders. Preclinical data suggest that these receptors also 
contribute to nicotine reward and dependence. Tobacco smoking may confound clinical studies of 
psychiatric disorders because many patients with such disorders smoke tobacco. Whether human 
subjects who smoke tobacco but are otherwise healthy have altered CB1 receptor binding in brain 
is unknown.
METHODS: We measured CB1 receptors in brains of 18 healthy men who smoke tobacco 
(frequent chronic cigarette smokers), and 28 healthy men who do not smoke tobacco, using 
positron emission tomography and [18F]FMPEP-d2, a radioligand for CB1 receptors. We collected 
arterial blood samples during scanning to calculate the distribution volume (VT), which is nearly 
proportional to CB1 receptor density. Repeated-measures analysis of variance compared VT 
between groups in various brain regions.
RESULTS: Brain CB1 receptor VT was about 20% lower in subjects who smoke tobacco than in 
subjects who do not. Decreased VT was found in all brain regions, but reduction did not correlate 
with years of smoking, number of cigarettes smoked per day, or measures of nicotine dependence.
CONCLUSIONS: Tobacco-smoking healthy men have a widespread reduction of CB1 receptor 
density in brain. Reduction of CB1 receptors appears to be a common feature of substance use 
disorders. Future clinical studies on the CB1 receptor should control for tobacco smoking.
Keywords
Addiction; Brain imaging; Cannabinoid CB1 receptor; Positron emission tomography; Smoking; 
Tobacco
The brain cannabinoid system is involved in the addictive properties of a variety of 
substances of abuse (1). CB1 cannabinoid receptors are located presynaptically in multiple 
brain regions, including the ventral tegmental area in the midbrain, where release of gamma-
aminobutyric acid (2) and glutamate are inhibited and dopamine release is modulated in 
response to many substances of abuse (3,4). We previously used positron emission 
tomography (PET) and an inverse agonist radioligand for CB1 receptors, [18F]FMPEP-d2 
(5,6), to examine CB1 receptor binding in human brain in two substance use disorders: 
cannabis and alcohol. In chronic daily cannabis smokers, we found regionally selective and 
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reversible downregulation of CB1 receptors; receptor binding was decreased in cortical 
regions but not in subcortical regions, and it returned to normal levels after about 4 weeks of 
monitored cannabis abstinence (7). In alcohol dependence, we found widespread and 
irreversible downregulation; receptor binding was decreased in both cortical and subcortical 
brain regions, and it remained similarly decreased after 2 to 4 weeks of monitored 
abstinence (8).
Tobacco is the most prevalent substance of abuse, with high addictive potential. Whether 
tobacco smoking affects CB1 receptor binding in human brain is unknown but is of 
importance for two reasons. First, preclinical and clinical observations suggest that CB1 
receptors are involved in nicotine addiction. In animal studies, blockade of CB1 receptors 
reduced nicotine-seeking behaviors and nicotine-induced midbrain dopamine release (9). In 
humans, rimonabant, a CB1 receptor inverse agonist, was effective in smoking cessation 
(10,11). Second, many patients with psychiatric disorders smoke tobacco, which can be a 
significant confound in clinical studies examining CB1 receptor binding in such disorders. In 
the current study, we evaluated CB1 receptor binding in healthy men who smoke tobacco 
cigarettes, in comparison with men who do not smoke, using PET and [18F]FMPEP-d2.
METHODS AND MATERIALS
The National Institutes of Health Combined NeuroScience Institutional Review Board 
approved the protocol and the consent forms. Written informed consent was obtained from 
all subjects.
Subjects
Healthy men (n = 46) were free of somatic and psychiatric illness as confirmed by history, 
physical examination, structured diagnostic interviews (Structured Clinical Interview for 
DSM-IV, full version), electrocardiogram, and blood and urine tests. Subjects did not have 
current or lifetime history of substance use disorders (except for tobacco use disorder in the 
tobacco smokers) and had urine samples negative for cannabinoids, opiates, amphetamines, 
cocaine metabolites, and benzodiazepines during screening. We did not test for these urine 
markers on the day of the PET scan. Subjects had <10 lifetime exposures to cannabis and no 
use in the preceding 3 months. Recent heavy alcohol use was excluded by Alcohol Use 
Disorder Identification Test scores of ≤9 and no alcohol use during the 3 days prior to the 
PET scan. We did not systematically record caffeine consumption. In total, 18 subjects 
smoked cigarettes and 28 did not (Table 1). None of the nonsmokers was an ex-smoker. We 
recorded average number of cigarettes per day, age at onset of smoking, duration of 
smoking, and Fagerström Test for Nicotine Dependence scores. On average, smokers 
consumed 12 cigarettes per day (data available from 16 subjects) and had a Fagerström Test 
for Nicotine Dependence score of 4 (data available from 16 subjects), consistent with mild to 
moderate tobacco use disorder. Data from 32 (70%) of the subjects were published 
previously. We previously found that carriers of the C allele of a common single-nucleotide 
polymorphism, rs2023239, in the gene coding for the CB1 receptor (CNR1), have higher 
[18F]FMPEP-d2 binding than noncarriers. (8). We had these data available for 43 subjects 
(16 smokers and 27 nonsmokers). Genotyping was done as described previously (8).
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PET and Measurement of Parent Radioligand in Arterial Plasma
[18F]FMPEP-d2 was prepared as described previously (6) and in detail in our investigational 
new drug application (No. 105,198) submitted to the U.S. Food and Drug Administration 
(available at https://pdsp.unc.edu/databases/snidd/). The radioligand was obtained in high 
radiochemical purity (>99%) and had a molar activity of 107 ± 46 MBq/nmol at time of 
injection. The actual injected amount of [18F]FMPEP-d2 was somewhat higher in smokers 
than in nonsmokers (Table 1). However, the maximum mass dose (2 μg) was still within 
tracer dose limits with no significant expected CB1 receptor occupancy. With this maximum 
dose, we estimate the occupancy to be 0.1% using calculations and assumptions published 
previously (5).
After intravenous injection of [18F]FMPEP-d2 (Table 1), images were acquired for 120 
minutes using an Advance camera (GE Healthcare, Milwaukee, WI) as described previously 
(5). We did not use motion correction during PET imaging. PET scans were performed at 
least 4 hours after last tobacco use. We did not record time of last tobacco exposure. Arterial 
blood samples were drawn as described previously (7). The plasma time-activity curve was 
corrected for the fraction of unchanged radioligand by radio-high-performance liquid 
chromatography separation (12), and the plasma-free fraction was measured by 
ultrafiltration (13).
For anatomical reference, 3D T1-weighted magnetic resonance images were acquired at 3T 
using either the GE Signa scanner (GE Healthcare) or the Philips Achieva scanner (Philips 
Healthcare, Andover, MA). These high-resolution anatomical images had a voxel size of 
0.86 mm × 0.86 mm × 1.2 mm (transaxial acquisition; GE Healthcare) or 1 mm × 0.94 mm 
× 0.94 mm (sagittal acquisition; Philips Healthcare). Time of repetition, echo time length, 
and flip angle were 7.3 ms, 2.8 ms, and 6° for GE Healthcare and 8.1 ms, 3.7 ms, and 8° for 
Philips Healthcare, respectively. PET images were analyzed by applying a template of 
volumes of interest (14) as implemented in PMOD (version 3.0; PMOD Technologies, 
Zurich, Switzerland) (15) in the standard stereotactic space (16) as described previously (7). 
Distribution volume (VT) was estimated according to the two-tissue compartmental model 
(17) with concentration of parent radioligand in plasma as input function using PMOD as 
described previously (5). Statistical parametric mapping of VT values at voxel level was 
done using SPM8 as described previously (7), with body mass index (BMI) as a covariate. 
VT can also be conceptualized as ratio of area under the time-activity curve extrapolated into 
infinity of brain to plasma. To ensure that groups had similar input functions, plasma time-
activity curve of the parent radioligand was normalized for injected dose and body weight, 
expressed as standardized uptake values, and extrapolated into infinity using rate constants 
from triexponential fitting. Area under this curve was then calculated and compared between 
groups.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics 23.0 for Mac (version 24.0.0; IBM Corp., 
Armonk, NY). Variance was homogeneous across groups according to Levene’s test. 
Baseline characteristics of participants (Table 1) were compared using two-tailed t tests. To 
test whether CB1 receptors were decreased in subjects who smoke tobacco, we used a 
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mixed-model two-way analysis of variance (ANOVA) with group status (smoker vs. 
nonsmoker) as between-subject factor and brain region as within-subject factor. BMI entered 
the model as a covariate because it affects VT (7). Correlations with clinical variables were 
assessed with Pearson’s correlation coefficients. Nominal data were compared using 
Pearson’s χ2 test. Any p values less than .05 were considered statistically significant in the 
ANOVA. In the presence of significant main effects and interactions, regional contrasts were 
examined using post hoc t tests of marginal means from the ANOVA, and effect sizes were 
calculated as absolute difference between group means divided by pooled estimate of 
standard deviation, which was calculated assuming that pooled estimate of variance is the 
sample size-weighted average of sample variances. Because these regional contrasts were 
assessed only after significant ANOVA findings, they were not corrected for multiple 
comparisons.
Because many patients with psychiatric and substance use disorders also smoke tobacco, we 
wondered whether tobacco smoking confounded our previous findings of CB1 receptor 
downregulation in individuals with cannabis or alcohol use disorder. To examine this, we 
combined all data from these three datasets (46 healthy subjects [18 tobacco smokers and 28 
tobacco nonsmokers], 30 cannabis smokers [24 tobacco smokers and 6 tobacco 
nonsmokers], and 18 patients with alcohol dependence [11 tobacco smokers and 7 tobacco 
nonsmokers]) in an overall ANOVA model to assess the main effect of cigarette smoking 
across all subject groups. In this model, we looked at main effects of tobacco smoking, BMI, 
group status, and rs2023239 C allele carrier status.
RESULTS
The VT of [18F]FMPEP-d2 was lower in tobacco smokers than in nonsmokers (main effect 
of group: F = 8.30, p = .006). VT was lower in smokers in all brain regions, and the 
magnitude of this decrease differed significantly among brain regions (group × region 
interaction: F = 3.03, p = .029) (Figures 1 and 2 and Table 2). Decrease in BMI-adjusted VT 
ranged from 15% in the parietal cortex to 34% in white matter. The main effect of smoking 
was also significant when analyzed without correcting for BMI (F = 8.43, p = .006). 
Decreased VT in smokers was confirmed with an independent voxel-based whole-brain 
analysis (Figure 3). Among subjects who had available rs2023239 genotype data (n = 43 
subjects), 8 of 27 non-smokers (29%) and 2 of 16 smokers (13%) carried the C allele (χ2 = 
1.7, p = .199). When genotype entered the model, the main effect of smoking persisted (F = 
5.26, p = .026), although the main effect of genotype did not reach statistical significance (F 
= 1.44, p = .238).
Decreased VT was not caused by higher plasma protein binding in smokers given that 
fraction of free radioligand in plasma was not significantly different between groups (Table 
1). Area under the plasma time-activity curve of the parent radioligand extrapolated into 
infinity was similar between smokers (172 ± 53 standardized uptake values × minutes) and 
nonsmokers (167 ± 60 standardized uptake values × minutes) (mean ± SD; p = .789, t test), 
confirming similar input function. Although this measure was similar between groups, VT 
measurement is independent of the form of the input function and does not require it to be 
the same between groups to accurately quantify receptor availability.
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Among smokers, whole brain VT did not correlate with number of cigarettes smoked per day 
(R = −.27, p = .319), score on the Fagerström Test for Nicotine Dependence (R = −.14, p = .
611), lifetime duration of tobacco smoking (R =.21, p = .479), or age at onset of tobacco 
smoking (R = .18, p = .544).
In the combined analysis of 94 subjects (46 healthy subjects, 30 cannabis smokers, and 18 
patients with alcohol dependence), we found a significant main effect of tobacco smoking on 
CB1 receptor VT (smaller VT in tobacco smokers; F = 4.10, p = .046) and the expected 
significant main effects of BMI (F = 8.90, p = .004) and substance use disorder status (F = 
6.38, p = .003). When genotype entered the model (n = 91 subjects), the main effect of 
tobacco smoking diminished somewhat (F = 2.66, p = .106) and the main effect of genotype 
was significant (F = 4.45, p = .038). Tobacco smoking had no effect among cannabis 
smokers (F = 0.02, p = .894) or individuals with alcohol dependence (F = 0.40, p = .537) as 
also reported previously. Thus, tobacco smoking produced no additive CB1 receptor 
downregulation in individuals with cannabis or alcohol use disorder (Supplemental Figure 
S1). However, this post hoc cross-sectional comparison should be interpreted with caution 
because the original studies were not specifically designed to examine effects of tobacco 
smoking. Therefore, we cannot definitively rule out the possibility that tobacco smoking 
affected comparisons between healthy subjects and cannabis smokers or patients with 
alcohol dependence.
DISCUSSION
We found about 20% lower VT of [18F]FMPEP-d2 in tobacco-smoking healthy subjects 
compared with nonsmoking subjects, consistent with CB1 receptor downregulation. This 
reduction was significant in all brain regions, although some regions had larger reduction 
than others. Together with our previous data from individuals with cannabis or alcohol use 
disorder, these data support a role for brain CB1 receptors in various substance use disorders.
Previous animal studies on the effects of chronic nicotine exposure on CB1 receptor density 
produced inconsistent findings. Some studies on juvenile or adolescent rats have shown 
decreased hippocampal CB1 receptor messenger RNA (18), decreased cingulate cortex CB1 
receptor density (19), and decreased striatal CB1 receptor density as well as increased 
hippocampal CB1 receptor density (20). One study found increased CB1 receptor binding 
after adolescent exposure but unchanged binding after adult exposure (21). In contrast to 
juvenile or adolescent rodents, adult rodents generally were not found to have significant 
changes in CB1 receptors after chronic nicotine exposure (22,23). A previous micro-PET 
study with [18F]MK-9470, another radioligand for CB1 receptors, did not find significant 
changes in binding in rat brain after chronic nicotine exposure (24). These discrepancies in 
previous preclinical studies may be explained by differences in measuring techniques and 
age at nicotine exposure. With regard to adolescent versus adult exposure, we found no 
correlations between CB1 receptor binding and age at onset of tobacco smoking. That is, we 
found no evidence that CB1 receptor downregulation was more pronounced in subjects who 
started smoking at a younger age (<18 years; n = 6 subjects), although all subjects had adult 
exposure whether or not they were already exposed during adolescence.
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Lower CB1 receptor binding may be a common imaging biomarker for several substances of 
abuse (25). These receptors are found throughout the brain, and the changes are often seen in 
widespread areas such as those found in tobacco smokers in the current study and in alcohol-
dependent individuals previously (8). Such widespread downregulation may reflect 
increased overall tone of endogenous cannabinoids, which could be viewed as a 
neuroprotective compensatory mechanism. Chronic nicotine administration may 
downregulate CB1 receptors by chronic overstimulation by endogenous cannabinoids (9), 
similar to what is hypothesized to occur with chronic alcohol consumption (8,26). In 
contrast, cannabis smokers have CB1 receptor downregulation only in neocortical brain 
regions but not in the basal ganglia, midbrain, or cerebellum (7). This regional dissimilarity 
between substance use disorders may be partly explained by different mechanisms of action 
of these drugs; the psychoactive ingredient of cannabis, Δ9-tetrahydrocannabinol, binds to 
CB1 receptors directly, whereas nicotine and alcohol affect CB1 receptors indirectly via 
endogenous cannabinoids (1).
In contrast to our finding in healthy subjects, a recent PET study found higher brain CB1 
receptor binding in patients with schizophrenia who smoked tobacco compared with patients 
who did not smoke, although both patient cohorts had lower CB1 receptor binding than 
healthy nonsmoking control subjects (27). Together with our previous findings of no effects 
of tobacco smoking in subjects with cannabis use disorder (7) or alcohol use disorder (8), 
this pattern of results suggests that tobacco smoking has different effects on brain CB1 
receptors in healthy subjects than in subjects with neuropsychiatric illness.
A potential site for a functional connection between nicotine and endocannabinoid 
neurotransmission is the midbrain dopamine neurons projecting to ventral parts of the 
striatum, including the nucleus accumbens, considered to be a critical part of the brain 
reward circuit (4). Nicotinic acetylcholine receptor subtype α4β2 on gamma-aminobutyric 
acidergic and dopaminergic neurons and receptor subtype α7 on glutamatergic terminals are 
targets for mediating rewarding actions of nicotine (28). Acute nicotine exposure increases 
dopamine concentration in the nucleus accumbens, an effect that can be reduced by blocking 
CB1 receptors (29). In the midbrain ventral tegmental area, acute nicotine exposure increases 
endo-cannabinoid levels (30), providing further evidence of endo-cannabinoid modulation of 
nicotine reward. In the midbrain, CB1 receptors are located in presynaptic terminals of both 
excitatory and inhibitory neurons, so functional responses to increased endocannabinoids 
may be complex (28). In addition, non-cannabinoid receptor targets are likely affected by 
endogenous cannabinoids (28).
Clinical trials showed the efficacy of rimonabant, a CB1 receptor inverse agonist, in 
promoting smoking cessation (10,11), supporting the role of CB1 receptors in nicotine 
dependence. However, clinical use of this drug is limited by psychiatric side effects. 
Although CB1 blockade may acutely reduce nicotine-induced mesolimbic dopamine release 
(29), it might not reverse all cannabinoid effects of nicotine because CB1 receptors are 
downregulated. Enhancing endogenous cannabinoid function in withdrawal and chronic 
abstinence might intuitively seem to be a way to compensate for such downregulation, 
although we do not yet know whether CB1 receptors return to normal levels after abstinence 
from nicotine. Preclinical studies investigating the impact of blocking the enzyme that 
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breaks down some endocannabinoids (fatty acid amide hydrolase) do not fully agree on the 
utility of this approach (9), which may reflect the complexity of endo-cannabinoid 
modulation of drug action.
We did not find correlations between amount of tobacco exposure and CB1 receptor 
downregulation. A potential limitation of this study is that we did not measure 
concentrations of nicotine or any of its metabolites, such as cotinine, which would give more 
accurate estimates of prior tobacco exposure than retrospective self-reports of years of 
smoking and number of cigarettes per day.
Decreased VT of [18F]FMPEP-d2 likely represents decreased number of CB1 receptors 
rather than occupancy of receptors by endocannabinoids. As we argued previously (7,8), 
about 90% of VT represents specific binding in monkey brain (5). In rodent brain, binding of 
[11C]MePPEP, a close radioligand analog of [18F]FMPEP-d2, could not be displaced by 
endogenous cannabinoids (31), suggesting that decreased VT of [18F]FMPEP-d2 observed in 
the current study is not due to increased levels of endocannabinoids. Finally, the outcome 
measure VT corrects for possible group differences in peripheral distribution and metabolism 
of the radioligand.
The current study has several limitations. First, we studied only male subjects, as we had 
done previously in studies on cannabis use (7) and alcohol dependence (8); therefore, 
whether these results are generalizable to women remains to be determined. Studying only 
male subjects limits our understanding of endocannabinoid function in substance use 
disorders. Second, altered nondisplaceable binding may have confounded our measurements 
because VT is a composite measure of specific and nondisplaceable binding. However, the 
contribution of nondisplaceable binding is rather small (~10%) (5) and does not vary 
substantially among brain regions, such that it is unlikely to fully explain the 20% to 30% 
lower VT in tobacco smokers than in non-smokers. Third, although we excluded significant 
cannabis or alcohol exposure, we did not systematically assess caffeine consumption. 
Caffeine may influence CB1 receptors via adenosine receptors (32).
In summary, we showed that tobacco smoking is associated with widespread downregulation 
of CB1 receptors in human brain. This finding adds to the growing evidence for CB1 
receptor abnormalities in substance use disorders and suggests that future clinical studies on 
this receptor target should carefully control for tobacco smoking.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Distribution volume (VT) of [18F]FMPEP-d2 (a measure of cannabinoid CB1 receptor 
density) is lower in male tobacco smokers (black bars, n = 18) than in nonsmokers (gray 
bars, n = 28) in both cortical and subcortical regions. Values are estimated marginal means 
from the repeated-measures analysis of variance and are adjusted to an average body mass 
index of 26.8 kg/m2. Error bars are standard error of the mean. *p < .05; **p < .005; post 
hoc contrasts of marginal means from analysis of variance. ACC, anterior cingulate cortex; 
AMY, amygdala; CAU, caudate nucleus; CER, cerebellum; HIPP, hippocampus; INS, insula; 
MIDBR, midbrain; OCC, occipital cortex; PAR, parietal cortex; PCC, posterior cingulate 
cortex; PFC, prefrontal cortex; PHIPP, parahippocampal gyrus; PUT, putamen; TEMP, 
lateral temporal cortex; THA, thalamus; VST, ventral striatum; WM, white matter.
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Figure 2. 
Individual body mass index–adjusted [18F]FMPEP-d2 distribution volume (VT) values in 
average cortical, subcortical, and white matter regions in nonsmokers (open circles) and 
smokers (closed circles).
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Figure 3. 
Whole-brain statistical parametric mapping analysis shows lower cannabinoid CB1 receptor 
density (distribution volume [VT]) in male tobacco smokers (n = 18) than in nonsmokers (n 
= 28) as a large single cluster. This cluster comprised 132,291 voxels with a maximum t 
value of 6.0 at [22, 10, 46] and a cluster-level familywise error corrected p value of <.001. 
Color bar represents t value in each voxel within the significant cluster. (A) Transaxial 
section. (B) Coronal section. (C) Sagittal section.
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Table 2.
Group Comparisons of Regional [18F]FMPEP-d2 Unadjusted VT Values
Brain Region % Difference Effect Size p Value
Anterior Cingulate Cortex −23 0.81 .012
Amygdala −23 0.77 .016
Caudate Nucleus −22 0.77 .017
Cerebellum −19 0.83 .009
Hippocampus −19 0.70 .029
Insula −25 0.92 .004
Midbrain −28 1.12 .001
Occipital Cortex −17 0.74 .019
Parietal Cortex −15 0.62 .050
Pons −24 1.04 .001
Posterior Cingulate Cortex −24 0.92 .005
Prefrontal Cortex −17 0.71 .028
Parahippocampal Gyrus −21 0.75 .019
Putamen −25 0.85 .008
Lateral Temporal Cortex −20 0.79 .014
Thalamus −20 0.81 .011
Ventral Striatum −20 0.73 .002
White Matter −34 1.02 .002
Effect sizes were calculated as absolute difference of group mean values divided by a pooled estimate of standard deviation, which was calculated 
assuming that pooled estimate of variance is the sample size-weighted average of sample variances. The p values are from post hoc comparisons of 
estimated marginal means from the repeated-measures analysis of variance model (including body mass index as a covariate).
VT, distribution volume.
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